The Supreme Court will start final hearing next month on a plea by Swiss pharma firm Novartis AG challenging the order of an appellate board, which upheld the government’s denial of patent to its blood cancer drug Glivec.
A Bench, comprising Justices Dalveer Bhandari and Deepak Verma, directed today to list the matter for final hearing in March.
Listed for hearing on 09/08/2011 (update: Moneycontrol news)
Background: Novartis’ imatinib crystalline form application [1602/MAS/1998] rejected in pre grant opposition and also in appeal at IPAB . This case is precedential for the term “efficacy” of section 3(d) (efficacy=therapeutic efficacy). Now the appeal of IPAB order lies with supreme court.